Recursion Pharmaceuticals
RXRX
RXRX
333 hedge funds and large institutions have $1.61B invested in Recursion Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 138 increasing their positions, 67 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
333
Holders Change
+21
Holders Change %
+6.73%
% of All Funds
4.52%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.12%
New
66
Increased
138
Reduced
67
Closed
41
Calls
$28.3M
Puts
$21.7M
Net Calls
+$6.56M
Net Calls Change
+$6.77M
Top Buyers
| 1 |
1
UBS AM
Chicago,
Illinois
|
$33.9M |
| 2 |
2
UBS Group
Zurich,
Switzerland
|
$29.5M |
| 3 |
AIM
3
ARK Investment Management
St. Petersburg,
Florida
|
$184M |
| 4 |
4
Morgan Stanley
New York
|
$26.5M |
| 5 |
KA
5
Kinnevik AB
Stockholm,
Sweden
|
$71.1M |
